Functions of non-coding RNAs in regulating cancer drug targets

Acta Biochim Biophys Sin (Shanghai). 2022 Mar 25;54(3):279-291. doi: 10.3724/abbs.2022006.

Abstract

With the development of precision medicine, the efficiency of tumor treatment has been significantly improved. More attention has been paid to targeted therapy and immunotherapy as the key to precision treatment of cancer. Targeting epidermal growth factor receptor (EGFR) has become one of the most important targeted treatments for various cancers. Comparing with traditional chemotherapy drugs, targeting EGFR is highly selective in killing tumor cells with better safety, tolerability and less side effect. In addition, tumor immunotherapy has become the fourth largest tumor therapy after surgery, radiotherapy and chemotherapy, especially immune checkpoint inhibitors. However, these treatments still produce a certain degree of drug resistance. Non-coding RNAs (ncRNAs) were found to play a key role in carcinogenesis, treatment and regulation of the efficacy of anticancer drugs in the past few years. Therefore, in this review, we aim to summarize the targeted treatment of cancers and the functions of ncRNAs in cancer treatment.

Keywords: EGFR; drug resistance; immune checkpoint inhibitor; non-coding RNA (ncRNA); precision medicine.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • ErbB Receptors
  • Humans
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • RNA, Long Noncoding* / genetics
  • RNA, Untranslated / genetics
  • RNA, Untranslated / therapeutic use

Substances

  • Antineoplastic Agents
  • RNA, Long Noncoding
  • RNA, Untranslated
  • ErbB Receptors

Grants and funding

This work was supported by the grant from the Shanghai Science and Technology Committee (No. 20S11901300).